X-Linked

4

Review clinical trials related to X-Linked. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Participants needed: 70
Trial details
Phase: Phase 3Age: 7-16Biological sex: MaleType: InterventionalSponsor: Avidity Biosciences, Inc.Updated: Jul 13, 2026
Eligibility criteria

Ambulatory males with clinical and genetic diagnosis of DMD [+4]

Previous treatment cell or gene therapy. [+4]

Status: Not yet recruiting

Morphology in Oral Rare Syndromes & Artificial Intelligence for Clinical Diagnosis

MOSAIC aims to determine whether oro-dental morphological anomalies, particularly palatal morphology, associated with rare bone and cartilage diseases can be precisely characterized using 3D digital models analysed through geometric morphometrics. The study will also evaluate whether these morphological signatures can train an artificial intelligence (AI) algorithm to classify syndromes. A prospective monocentric case-control cohort will be constituted, including 3D intra-oral scans and associated clinical data. The final goal is to improve diagnostic accuracy and reduce diagnostic delay in rare bone disorders.

Participants needed: 240
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University Hospital, BordeauxUpdated: Jun 24, 2026Locations: 1
Eligibility criteria

For cases: Diagnosis of a rare bone and cartilage disorder confirmed by the Rare... [+3]

History of major orthodontic/orthognathic treatment; [+3]

Status: Not yet recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Participants needed: 70
Trial details
Phase: Phase 3Age: 7-16Biological sex: MaleType: InterventionalSponsor: Avidity Biosciences, Inc.Updated: May 14, 2026
Eligibility criteria

Ambulatory males with clinical and genetic diagnosis of DMD [+4]

Previous treatment cell or gene therapy. [+4]

Status: Recruiting

Hemophilia A Research Program

This study longitudinally observes the intergenerational (mother-child) continuum in hemophilia A from pregnancy through early childhood. Because the study follows mother-child pairs, the study includes both a maternal cohort and a pediatric cohort. Each cohort has a primary goal: for the mother with a severe hemophilia genotype, the overarching primary goal is to understand the risks for pregnancy-associated bleeding and postpartum hemorrhage (PPH); for the child, the overarching primary goal is to understand the risks, timing, and circumstances of development of anti-FVIII antibodies. From a longitudinal perspective, risks for both bleeding in the mother and anti-FVIII antibody development in the child are expected to be influenced over time by genetic and environmental factors that begin early in (or before) pregnancy. Enrollment of blood relatives is offered to improve power to better understand inherited contributions to bleeding and inhibitor development in the mother-baby pairs.

Participants needed: 500
Trial details
Biological sex: AllType: ObservationalSponsor: University of WashingtonUpdated: Feb 17, 2026Locations: 1
Eligibility criteria

Currently pregnant and prior to 37 weeks gestation [+26]